16
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Cisplatin and carboplatin result in similar gonadotoxicity in immature human testis with implications for fertility preservation in childhood cancer

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Clinical studies indicate chemotherapy agents used in childhood cancer treatment regimens may impact future fertility. However, effects of individual agents on prepubertal human testis, necessary to identify later risk, have not been determined. The study aimed to investigate the impact of cisplatin, commonly used in childhood cancer, on immature (foetal and prepubertal) human testicular tissues. Comparison was made with carboplatin, which is used as an alternative to cisplatin in order to reduce toxicity in healthy tissues.

          Methods

          We developed an organotypic culture system combined with xenografting to determine the effect of clinically-relevant exposure to platinum-based chemotherapeutics on human testis. Human foetal and prepubertal testicular tissues were cultured and exposed to cisplatin, carboplatin or vehicle for 24 h, followed by 24–240 h in culture or long-term xenografting. Survival, proliferation and apoptosis of prepubertal germ stem cell populations (gonocytes and spermatogonia), critical for sperm production in adulthood, were quantified.

          Results

          Cisplatin exposure resulted in a significant reduction in the total number of germ cells (− 44%, p < 0.0001) in human foetal testis, which involved an initial loss of gonocytes followed by a significant reduction in spermatogonia. This coincided with a reduction (− 70%, p < 0.05) in germ cell proliferation. Cisplatin exposure resulted in similar effects on total germ cell number (including spermatogonial stem cells) in prepubertal human testicular tissues, demonstrating direct relevance to childhood cancer patients. Xenografting of cisplatin-exposed human foetal testicular tissue demonstrated that germ cell loss (− 42%, p < 0.01) persisted at 12 weeks. Comparison between exposures to human-relevant concentrations of cisplatin and carboplatin revealed a very similar degree of germ cell loss at 240 h post-exposure.

          Conclusions

          This is the first demonstration of direct effects of chemotherapy exposure on germ cell populations in human foetal and prepubertal testis, demonstrating platinum-induced loss of all germ cell populations, and similar effects of cisplatin or carboplatin. Furthermore, these experimental approaches can be used to determine the effects of established and novel cancer therapies on the developing testis that will inform fertility counselling and development of strategies to preserve fertility in children with cancer.

          Supplementary information

          The online version contains supplementary material available at 10.1186/s12916-020-01844-y.

          Related collections

          Most cited references34

          • Record: found
          • Abstract: found
          • Article: not found

          Cisplatin in cancer therapy: molecular mechanisms of action.

          Cisplatin, cisplatinum, or cis-diamminedichloroplatinum (II), is a well-known chemotherapeutic drug. It has been used for treatment of numerous human cancers including bladder, head and neck, lung, ovarian, and testicular cancers. It is effective against various types of cancers, including carcinomas, germ cell tumors, lymphomas, and sarcomas. Its mode of action has been linked to its ability to crosslink with the purine bases on the DNA; interfering with DNA repair mechanisms, causing DNA damage, and subsequently inducing apoptosis in cancer cells. However, because of drug resistance and numerous undesirable side effects such as severe kidney problems, allergic reactions, decrease immunity to infections, gastrointestinal disorders, hemorrhage, and hearing loss especially in younger patients, other platinum-containing anti-cancer drugs such as carboplatin, oxaliplatin and others, have also been used. Furthermore, combination therapies of cisplatin with other drugs have been highly considered to overcome drug-resistance and reduce toxicity. This comprehensive review highlights the physicochemical properties of cisplatin and related platinum-based drugs, and discusses its uses (either alone or in combination with other drugs) for the treatment of various human cancers. A special attention is paid to its molecular mechanisms of action, and its undesirable side effects. Copyright © 2014 Elsevier B.V. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Childhood and adolescent cancer statistics, 2014.

            In this article, the American Cancer Society provides estimates of the number of new cancer cases and deaths for children and adolescents in the United States and summarizes the most recent and comprehensive data on cancer incidence, mortality, and survival from the National Cancer Institute, the Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries (which are reported in detail for the first time here and include high-quality data from 45 states and the District of Columbia, covering 90% of the US population). In 2014, an estimated 15,780 new cases of cancer will be diagnosed and 1960 deaths from cancer will occur among children and adolescents aged birth to 19 years. The annual incidence rate of cancer in children and adolescents is 186.6 per 1 million children aged birth to 19 years. Approximately 1 in 285 children will be diagnosed with cancer before age 20 years, and approximately 1 in 530 young adults between the ages of 20 and 39 years is a childhood cancer survivor. It is therefore likely that most pediatric and primary care practices will be involved in the diagnosis, treatment, and follow-up of young patients and survivors. In addition to cancer statistics, this article will provide an overview of risk factors, symptoms, treatment, and long-term and late effects for common pediatric cancers. © 2014 American Cancer Society, Inc.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The side effects of platinum-based chemotherapy drugs: a review for chemists

              The platinum chemotherapy drugs cisplatin, carboplatin, and oxaliplatin are known to cause seven different types of side effects in patients. The platinum-based drugs cisplatin, carboplatin and oxaliplatin are regularly prescribed in the treatment of cancer and while they are effective, their use is limited by their severe, dose-limiting side effects (also referred to as adverse effects/events). In total, a cancer patient can experience any combination of around 40 specific side effects. The dose-limiting side effect for cisplatin is nephrotoxicity, for carboplatin it is myelosuppression, and for oxaliplatin it is neurotoxicity. Other common side effects include anaphylaxis, cytopenias (including leukopenia and neutropenia, thrombocytopenia, and anaemia), hepatotoxicity, ototoxicity, cardiotoxicity, nausea and vomiting, diarrhea, mucositis, stomatitis, pain, alopecia, anorexia, cachexia, and asthenia. The side effects may require patients to be prescribed dose reductions in their platinum drugs of between 25 and 100%. Furthermore, patients require extensive monitoring of their biochemistries, kidney and liver function, and depending on the drug, hearing tests. Finally, patients are commonly co-prescribed additional non-chemotherapy based drugs to treat the side effects which can include antiemetics, antibiotics and myeloid growth factors, mannitol, propafenone, saline hyperhydration, magnesium supplements, monoclonal antibody cytokine blockers, and antioxidants.
                Bookmark

                Author and article information

                Contributors
                rod.mitchell@ed.ac.uk
                Journal
                BMC Med
                BMC Med
                BMC Medicine
                BioMed Central (London )
                1741-7015
                4 December 2020
                4 December 2020
                2020
                : 18
                : 374
                Affiliations
                [1 ]GRID grid.4305.2, ISNI 0000 0004 1936 7988, MRC Centre for Reproductive Health, , The Queen’s Medical Research Institute, The University of Edinburgh, ; 47 Little France Crescent, Edinburgh, EH16 4TJ Scotland, UK
                [2 ]GRID grid.414963.d, ISNI 0000 0000 8958 3388, KK Women’s and Children’s Hospital, ; Bukit Timah Rd, 100, Singapore, 229899 Singapore
                [3 ]GRID grid.496757.e, ISNI 0000 0004 0624 7987, Edinburgh Royal Hospital for Sick Children, ; 9 Sciennes Road, Edinburgh, EH9 1LF Scotland, UK
                [4 ]GRID grid.24381.3c, ISNI 0000 0000 9241 5705, NORDFERTIL Research Lab Stockholm, Childhood Cancer Research Unit, Department of Women’s and Children’s Health, , Karolinska Institutet and Karolinska University Hospital, ; Stockholm, Sweden
                [5 ]Division of Haematology-Oncology and Stem Cell Transplantation, Children’s Hospital, University of Helsinki, Helsinki University Central Hospital, Helsinki, Finland
                [6 ]GRID grid.4991.5, ISNI 0000 0004 1936 8948, Radcliffe Department of Medicine, , MRC Weatherall Institute of Molecular Medicine, University of Oxford, ; Oxford, OX39DS UK
                [7 ]GRID grid.4991.5, ISNI 0000 0004 1936 8948, Department of Paediatrics and Child Health, , Oxford University Hospitals NHS Foundation Trust, and Nuffield Department of Womens and Reproductive Health, University of Oxford, ; Oxford, UK
                [8 ]GRID grid.223827.e, ISNI 0000 0001 2193 0096, Section of Andrology, Division of Urology, Department of Surgery, , University of Utah School of Medicine, ; Salt Lake City, UT USA
                [9 ]GRID grid.223827.e, ISNI 0000 0001 2193 0096, Howard Hughes Medical Institute, Department of Oncological Sciences and Huntsman Cancer Institute, , University of Utah School of Medicine, ; Salt Lake City, UT USA
                [10 ]GRID grid.475435.4, Department of Growth and Reproduction, , Copenhagen University Hospital (Rigshospitalet), ; Blegdamsvej 9, 2100 Copenhagen, Denmark
                [11 ]GRID grid.4305.2, ISNI 0000 0004 1936 7988, Biomedical Sciences, , University of Edinburgh, ; Edinburgh, EH8 9XD UK
                Article
                1844
                10.1186/s12916-020-01844-y
                7716476
                33272271
                ec928148-bf46-48a2-9031-82aa88c9861c
                © The Author(s) 2020

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 22 July 2020
                : 6 November 2020
                Funding
                Funded by: Medical Research Council
                Award ID: MR/S017151/1
                Award ID: MR/N022556/1
                Funded by: Children with Cancer UK
                Award ID: 15-198
                Funded by: FundRef http://dx.doi.org/10.13039/100010269, Wellcome Trust;
                Award ID: 098522
                Funded by: Swedish Childhood Cancer Foundation
                Award ID: TJ20200023
                Award Recipient :
                Funded by: Birgitta and Carl-Axel Rydbeck’s Research Grant
                Award ID: 2020-00348
                Award Recipient :
                Categories
                Research Article
                Custom metadata
                © The Author(s) 2020

                Medicine
                human,testis,cisplatin,germ cell,fertility,prepubertal,foetal,xenograft
                Medicine
                human, testis, cisplatin, germ cell, fertility, prepubertal, foetal, xenograft

                Comments

                Comment on this article

                scite_
                0
                0
                0
                0
                Smart Citations
                0
                0
                0
                0
                Citing PublicationsSupportingMentioningContrasting
                View Citations

                See how this article has been cited at scite.ai

                scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

                Similar content109

                Cited by21

                Most referenced authors410